))
Episodes 46: Spiro Rombotis- CEO at Cyclacel
Manage episode 386335424 series 3526490
Contenuto fornito da Vial. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Vial o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
We’re thrilled to share our enlightening exchange with Spiro Rombotis, the seasoned CEO of Cyclacel. He peels back the curtain on the breakthrough discovery of B53, a commonly mutated gene in cancer patients, and the inspiring success of FADRA, their lead drug in clinical trials. Furthermore, Spiro delves into the highs and lows faced by Cyclacel, including the triumphant moment a patient was declared cancer-free thanks to their groundbreaking drug.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Capitoli
1. Episodes 46: Spiro Rombotis- CEO at Cyclacel (00:00:00)
2. Cancer Research and Drug Advancements (00:00:06)
3. Biotech and Clinical Research Opportunities (00:14:03)
4. Health Patient Advice for Success (00:20:50)
62 episodi
Condividi
